In the era of precision medicine, liquid biopsies are being increasingly integrated into clinical trial design, translational research studies, and clinical testing regimens. Solid tumor biopsies remain the gold-standard for the interrogation of the cancer genome, however the advent of liquid biopsies and multi-region tissue sampling has demonstrated that there can be more to a cancer’s genomic profile than that found in a single site biopsy.1 Moreover, the ease and non-invasive nature of the liquid biopsy facilitates multi-timepoint sampling to observe tumor evolution in real time.
However, the liquid biopsy alone may not capture all tumor variants if healthy cancer cells do not shed their contents into blood circulation.
NeXT Liquid Biopsy™, a first-of-its-kind, high-performance, exome-wide liquid biopsy assay, is designed to complement Personalis’ flagship tissue-based immunogenomics platform, ImmunoID NeXT™, providing a comprehensive platform to further enhance the development of more efficacious cancer therapies in later-stage solid tumor indications. By combining NeXT Liquid Biopsy with ImmunoID NeXT, researchers now have a powerful tool to overcome the complexities of spatial and temporal heterogeneity, longitudinally monitor clonal and subclonal dynamics, and interrogate mechanisms of acquired resistance at or before cancer progression (Figure 1).
Additionally, by virtue of a whole-exome approach, NeXT Liquid Biopsy provides researchers a unique ability to explore key areas of tumor biology that may not be accessible through focused, targeted panels.